Salix Pharmaceuticals to buy Santarus for $32/share

Salix Pharmaceuticals (SLXP) will acquire Santarus (SNTS) for $32/share, a 38% premium to today's close, valuing the company at ~$2.6B. (PR)

From other sites
Comments (2)
  • Growfast
    , contributor
    Comments (294) | Send Message
    Wow! Salix gets a great company but I was looking for the long-term ride in SNTS which is on a great track. Now, back to research on the combination to figure out if the ride continues.
    7 Nov 2013, 04:17 PM Reply Like
  • Red RuffnSore
    , contributor
    Comments (13) | Send Message
    Stock up, stock down. It doesn't seem to matter. The lawyers are already flying lazy circles over this deal. Yeah, I know, they're looking out for MY interests as a shareholder. How altruistic of them.
    8 Nov 2013, 09:30 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs